Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 24
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Staar Surgical Co
STAA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$22.61
0.12
0.53%
Dern. MÀJ: Oct 23, 4:00 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Résultats:
Résultats Q3 2026 dans dans 11 jours à partir de maintenant le mer. nov. 4th, après la fermeture du marché
Staar Surgical Financials
Staar Surgical (STAA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Staar Surgical Q2 EPS $0.16 Beats $0.15 Estimate, Sales $93.535M Beat $90.589M Estimate
Staar Surgical (NASDAQ:STAA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the
Benzinga Newsdesk
Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions
STAAR Surgical expects preliminary Q2 2026 net sales to top $90 million, driven by strong Americas growth and an inventory rebound in China.
Vandana Singh
PRO
STAAR Surgical Reports Q2 Preliminary Net Sales To Be Over $90M
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second
Benzinga Newsdesk
PRO
Staar Surgical Q1 EPS $0.10 Beats $(0.06) Estimate, Sales $93.522M Beat $75.509M Estimate
Staar Surgical (NASDAQ:STAA) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.06) by 266.67 percent. This is a 115.63 percent increase over losses of $(0.64) per share from
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Staar Surgical Q1 Revenue expected to be more than $90.000M vs $70.325M Est
Staar Surgical (NASDAQ:STAA) Q1 Revenue expected to be more than $90.000M vs $70.325M Est
Benzinga Newsdesk
